Cardica, FDA Seek To Account For Missing PAS Port Trial Patients
This article was originally published in The Gray Sheet
Executive Summary
FDA should shift the burden of evidence on anastomotic connector devices to postmarket trials because of difficulties in obtaining angiographic follow-up data in pivotal studies, Cardica maintains
You may also be interested in...
Cardica Claims Breakthrough In Endoscopic Heart Surgery
Widespread adoption of minimally invasive heart surgery as an alternative to both open surgery and percutaneous intervention could be just around the corner
Cardica Claims Breakthrough In Endoscopic Heart Surgery
Widespread adoption of minimally invasive heart surgery as an alternative to both open surgery and percutaneous intervention could be just around the corner
Earnings Calls In Brief
Cardica readies revised PAS-Port 510(k): Firm plans to submit a 510(k) application for its PAS-Port proximal anastomic connector system by the end of 2007 for use during coronary artery bypass graft surgery, assuming success of an ongoing pivotal trial in the U.S. and Europe, Cardica reports during a July 31 earnings call. FDA's Circulatory System Devices Panel had recommended against clearance of an earlier PAS-Port 510(k) submission in April 2005 due to insufficient data (1"The Gray Sheet" May 2, 2005, p. 14). Cardica gained CE mark approval in July for European marketing of its C-Port xA distal anastomosis system, its next-generation C-Port; the firm is awaiting FDA clearance of a December 2005 510(k) submission for the device. The firm also will pursue U.S. and European clearance of its C-Port Flex A anastomosis system for use in open chest surgery in the second half of fiscal 2007, which began July 1. Cardica was denied a new technology Medicare "add-on" payment for its C-Port system in CMS' final inpatient rule...